Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

9.44
+0.61006.91%
Post-market: 9.520.0800+0.85%19:59 EDT
Volume:27.29M
Turnover:263.21M
Market Cap:10.00B
PE:-9.55
High:10.09
Open:8.92
Low:8.90
Close:8.83
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:2.87
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-9.56
PE(LYR):-24.71

Loading ...

ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA

TIPRANKS
·
May 20

FDA accepts ImmunityBio sBLA for ANKTIVA plus BCG in papillary NMIBC

Reuters
·
May 20

Immunitybio Announces FDA Acceptance of Supplemental Bla for Anktiva® Plus Bcg in Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer With Papillary Disease; Pdufa Date Set for January 6, 2027

THOMSON REUTERS
·
May 20

Immunitybio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of Nai + Bcg Versus Nadofaragene and Tar-200 at Aua 2026

THOMSON REUTERS
·
May 19

ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis

Reuters
·
May 19

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Stalled Iran Peace Efforts, Inflation Concerns

MT Newswires Live
·
May 18

BRIEF-Immunitybio Announces Comprehensive U.S. Patents Covering Combination Of Anktiva With Bcg For Cancer Treatment

Reuters
·
May 18

ImmunityBio Secures Five US Patents for Cancer Treatment

MT Newswires Live
·
May 18

ImmunityBio wins five US patents for ANKTIVA-BCG cancer treatment combo through 2035

Reuters
·
May 18

Immunitybio Inc - Patents Cover Anktiva Plus Bcg for Bladder Cancer With Terms Through at Least 2035

THOMSON REUTERS
·
May 18

ImmunityBio Secures Exclusive Rights to Develop, Commercialize Tokyo-172 BCG in US

MT Newswires Live
·
May 18

ImmunityBio signs exclusive US supply deal with Japan BCG Laboratory for Tokyo BCG strain

Reuters
·
May 17

Immunitybio Signs Exclusive U.S. Agreement With Japan Bcg Laboratory for the Tokyo Strain of Bcg to Enhance Bcg Supply in the United States

THOMSON REUTERS
·
May 17

Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Dow Jones
·
May 15

Stock Track | ImmunityBio Plummets 5.93% Intraday as Q1 Losses Far Exceed Analyst Expectations

Stock Track
·
May 12

Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results

Simply Wall St.
·
May 11

Immunitybio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Stock Track | ImmunityBio Soars 5.61% Intraday on Positive Analyst Coverage and Buy Rating

Stock Track
·
May 09

Immunitybio Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
May 09

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)

TIPRANKS
·
May 08